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Abstract The role of the phospholipase C (PLC)Q2 isotype in
platelet activation was evaluated by studying PLCQ2 3/3 mice.
These mice have a prolonged bleeding time but their platelets
respond normally to non-collagenous agonists. PLCQ2-null
platelets show residual aggregation response to collagen ¢bres
(6% versus 74% for wild-type) with minimal granule secretion
and no shape change. A delayed shape change is observed at
later aggregation times. Speci¢c activation by glycoprotein
(GP)VI agonists (convulxin, collagen-related peptide and
GPVI crosslinking) is, however, abolished. Antibodies against
integrin K2L1 and GPVI each inhibit the residual collagen re-
sponse, implying a role of K2L1 in platelet activation and a
functional association with GPVI. These responses are also pre-
vented by blocking integrin KIIbL3 and phosphoinositide 3-ki-
nase, whereas aspirin treatment and ADP receptor blockade
only inhibit shape change. These results provide evidence for a
PLCQ2-independent collagen activation pathway requiring coop-
eration between GPVI and K2L1 leading to KIIbL3-dependent
aggregation and shape change by released ADP and thrombox-
ane A2.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Collagen ¢bres exposed at sites of vascular injury play a
crucial role in haemostasis and thrombosis by initiating plate-
let adhesion and activation. Several collagen receptors have
been identi¢ed on platelets, the two most important being the
integrin K2L1 (glycoprotein (GP)Ia^IIa, VLA2) and the immu-
noglobulin (Ig) superfamily protein GPVI [1,2]. Although the
di¡erent contributions of these two receptors are still subject
to debate, the currently favoured mechanism ascribes roles to
integrin K2L1 in platelet adhesion and to GPVI in platelet
activation [1,3]. GPVI-dependent signalling, which has been
studied in more detail, follows a pathway requiring the asso-
ciated FcRQ chain and culminates after a series of phosphor-
ylation steps in activation of phospholipase C (PLC)Q2 [4].
Studies with FcRQ-chain-de¢cient platelets, which lack
GPVI, or with platelets in which GPVI was depleted in vivo
by antibody treatment strongly suggest an essential role of
this receptor for collagen-induced activation [5,6]. The exis-
tence of an K2L1 signalling pathway remains controversial
with reports of weak KIIbL3 activation, or the recent proposal
of a minor role of K2L1 in collagen responses based on studies
in knockout mice lacking K2 or L1 [7^9]. Analysis of collagen-
induced activation is further complicated by ampli¢cation
loops involving agonists like ADP and thromboxane A2
(TXA2) which are released from platelets and act on G pro-
tein-coupled receptors linked to PLCL [10].
Seven PLC isozymes belonging to the PLCL, Q and N fam-
ilies have been identi¢ed in platelets, the major isoforms being
PLCL2, PLCL3 and PLCQ2 [11]. A large number of platelet
agonists including ADP, thrombin and TXA2 activate PLCL
isozymes through GKq protein-coupled receptors [12]. Colla-
gen and immune complexes acting on GPVI and FcRQIIA
respectively appear to activate PLCQ2 on the basis of obser-
vations of PLCQ2 phosphorylation or the presence of PLCQ2
in signalling complexes following platelet activation [13,14].
On the other hand, the role of PLCQ1 has been questioned,
at least with regard to collagen-induced activation, owing to
its lack of phosphorylation [13].
A straightforward analysis of the role of PLCQ2 in collagen-
triggered responses and more generally in agonist-induced
platelet activation has become feasible with the recent devel-
opment of PLCQ2 knockout mice [15,16]. These animals are
viable, despite defects in B cell maturation and signalling and
an intraperitoneal and gastrointestinal bleeding tendency [15].
Platelet aggregation and secretion were found to be normal in
PLCQ2-de¢cient mice in response to ADP or thrombin, but
abolished in response to collagen [15].
The aim of the present study was to examine in more detail
the contribution of PLCQ2 to platelet responses to collagen
and other physiological agonists. Collagen-induced platelet
activation and aggregation were severely decreased but not
fully abolished in PLCQ2-de¢cient mice, which responded nor-
mally to agonists acting through G protein-coupled receptors
but had a prolonged bleeding time. The residual activation
was found to be dependent on both GPVI and integrin K2L1
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and, through activation of phosphoinositide 3-kinase (PI3K)
and integrin KIIbL3, to lead to an ADP/TXA2-dependent re-
sponse.
2. Materials and methods
2.1. Materials
ADP was purchased from Roche Molecular Biochemicals (Meylan,
France). U46619, serotonin (5-HT), adrenaline, thrombin, arachidonic
acid, MRS 2179 and insoluble ¢brillar type I bovine collagen were
from Sigma (Saint-Quentin Fallavier, France). Horm ¢brillar type I
collagen from equine tendons was from Nycomed (Munchen, Ger-
many). Human ¢brinogen was from Kabi (Stockholm, Sweden) and
[3H]serotonin from Dupont NEN (Boston, MA, USA). Potato apy-
rase [17] and human von Willebrand factor (HvWF) [18] were puri¢ed
according to published procedures. The speci¢c ADP/ATPase ratio of
the apyrase is 1/8 with a 60 Wmol min31 mg31 speci¢c ADPase activ-
ity. AR-C69931MX was provided by Astra Charwood (Loughbor-
ough Leics, UK) while botrocetin was a gift from S. Jackson (Aus-
tralian Centre for Blood Diseases, Box Hill, Australia). Aspirin was
purchased from Synthelabo (Fallavier, France), LY294002 and Wort-
mannin were from Calbiochem (La Jolla, CA, USA) and the integrin
KIIbL3 antagonist Ro 43-5054 was provided by B. Steiner (Ho¡mann
LaRoche, Basel, Switzerland). HMK2, a monoclonal antibody (mAb)
against mouse integrin K2L1, was from PharMingen (La Jolla, CA,
USA) while rat anti-mouse integrin KIIbL3 (RAM.2), GPIbL
(RAM.1), GPIbK (RAM.6), CD9 (RAM.4), and GPVI (JAQ1) were
produced in our laboratories as described previously [6,19,20]. Ham-
ster anti-mouse GPV was kindly provided by Dr J. Fujimoto (Na-
tional Children’s Medical Research Center, Tokyo, Japan). Rabbit
anti-rat IgG was from Jackson Laboratories (West Grove, PA,
USA), collagen-related peptide (CRP) was provided by Dr R. Farn-
dale (University of Cambridge, UK) [21] and convulxin was a gift
from Dr M. Jandrot-Perrus (Faculte¤ Xavier Bichat, Paris, France)
[22].
2.2. Mouse strains
A PLCQ2-de¢cient mouse colony was established in the animal fa-
cilities of the Etablissement Franc,ais du Sang-Alsace by breeding
heterozygotes provided by Pr. J. Ihle (St. Jude Children’s Research
Hospital, Memphis, TN, USA). FcRQ-chain-de¢cient mice were ob-
tained from Taconic (Germantown, NY, USA).
2.3. Bleeding time
The bleeding time was measured by severing a 3 mm segment from
the distal tail of 8^10 week old mice. The amputated tail was imme-
diately immersed in isotonic saline at 37‡C and the time required for
the blood £ow to stop was recorded. If bleeding did not cease after 30
min, the tail was cauterised and v 1800 s was noted as the bleeding
time.
2.4. Platelet aggregation and secretion
Blood drawn into ACD-anticoagulant from the abdominal aorta of
four to six mice was pooled and platelets were washed and adjusted to
2.105/Wl in Tyrode’s bu¡er (12 mM NaHCO3, 0.3 mM NaH2PO4, pH
7.3, 137 mM NaCl, 2 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5.5 mM
glucose) containing 5 mM HEPES and 0.35% albumin [19]. Platelet
aggregation was measured turbidimetrically (Payton, Scarborough,
ON, Canada) [17]. A 450 Wl aliquot of platelet suspension was stirred
at 1100 rpm and activated by addition of di¡erent agonists (ADP,
arachidonic acid, collagen or U46619), in the presence of human ¢-
brinogen (55 Wg ml31) and in a ¢nal volume of 500 Wl. Secretion of the
dense granule contents during aggregation was determined as previ-
ously described using platelets loaded with [3H]serotonin in the wash-
ing procedure [10].
2.5. Scanning electron microscopy
Platelets were ¢xed in the aggregation cuvette by addition of 2.5%
glutaraldehyde in 0.1 M sodium cacodylate bu¡er (pH 7.3, 305 mOsm
kg31) containing 2% sucrose and incubation for 45 min at room
temperature. The ¢xed cells were allowed to adhere to poly-L-lysine-
coated slides. After three washes in 0.9% saline and dehydration in
graded ethanol solutions, the samples were air-dried with hexadi-
methyldisilazane, sputtered with gold and examined under a Hitachi
S-800 scanning electron microscope (Hitachi, Tokyo, Japan) (5 kV)
[10].
2.6. Statistical analysis
The statistical signi¢cance of di¡erences between means was eval-
uated using Student’s t-test for paired samples and P values of less
than 0.05 were considered to be signi¢cant.
3. Results
3.1. PLCQ2-de¢cient mice have a prolonged bleeding time
In an initial study PLCQ2-de¢cient mice were reported to
have a tendency to spontaneous bleeding [15]. To evaluate
more precisely a possible defect of primary haemostasis, stan-
dardised tail bleeding times were determined. The bleeding
time was signi¢cantly prolonged in PLCQ2 3/3 mice as com-
pared to heterozygotes or wild-type mice with a mixed genetic
background (median: 536 s versus 70 and 75 s respectively,
P6 0.0001) (Fig. 1).
3.2. Platelet aggregation responses of PLCQ2-de¢cient mice
The requirement for PLCQ2 in platelet responses to agonists
acting through di¡erent signalling pathways was assessed in
aggregation experiments. High concentrations of bovine or
equine ¢brillar type I collagen induced severely decreased ag-
gregation in PLCQ2 3/3 platelets (Fig. 2A and data not
shown). In contrast to the total lack of collagen-induced ag-
gregation reported by Wang et al., we nevertheless observed a
weak but highly reproducible aggregation response
(6.1 V 0.7% amplitude at 3 min for bovine collagen) in the
absence of a turbidimetrically measurable shape change.
This was followed after 4^5 min by a decrease in light trans-
mission and loss of scattering power, indicating a delayed
platelet shape change.
Normal aggregation was observed in PLCQ2 3/3 platelets
activated with low or high concentrations of ADP (0.25 and
1 WM) or thrombin (0.05 and 0.5 U ml31), arachidonic acid
(100 WM) or the TXA2 analogue U46619 (2 WM) (Fig. 2A and
data not shown). The shape change induced by serotonin and
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Fig. 1. PLCQ2-de¢cient mice have a prolonged bleeding time. Tail
bleeding times were measured in PLCQ2 +/+, +/3 and 3/3 mice as
described in Section 2. Symbols represent individual mice and the
median value for each population is indicated with a horizontal bar.
The bleeding time was signi¢cantly prolonged in PLCQ2 3/3 as
compared to PLCQ2 +/3 or PLCQ2 +/+ mice (median: 536 s
(n=20) versus 70 s (n=25) and 75 s (n=20) respectively,
***P6 0.0001).
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the potentiating e¡ect of adrenaline on ADP-induced aggre-
gation were also comparable in PLCQ2 +/+ and PLCQ2 3/3
cells (data not shown). Finally, PLCQ2-de¢cient platelets ag-
glutinated normally in response to vWF and botrocetin (Fig.
2B).
3.3. Morphological changes of PLCQ2-de¢cient platelets during
collagen-induced activation
PLCQ2 3/3 platelets challenged with collagen were ana-
lysed by scanning electron microscopy to better characterise
their morphological changes during low amplitude aggrega-
tion. Resting PLCQ2 3/3 platelets displayed a normal size
and disc-shaped structure as compared to PLCQ2 +/+ cells
(Fig. 3A,D). PLCQ2 +/+ platelets activated with 50 Wg ml31
collagen underwent a rapid (30 s) disc to sphere transforma-
tion, extended ¢lopodia upon adhesion to the collagen ¢bres
(Fig. 3B) and after 3 min formed large aggregates containing
tightly packed cells (Fig. 3C). Small aggregates of mostly dis-
coid platelets were observed in suspensions from PLCQ2 3/3
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Fig. 2. Platelet aggregation responses of PLCQ2-de¢cient mice. Ag-
gregation and agglutination responses of washed platelets from
PLCQ2 3/3 and +/+ mice. A: Aggregation induced by 50 Wg ml31
bovine collagen was strongly decreased in PLCQ2 de¢ciency and a
delayed shape change (grey arrow) was observed, while responses to
1 WM ADP and 0.5 U ml31 thrombin were not a¡ected. The base-
line is represented by a brocken line. B: Platelet agglutination in-
duced by 5 Wg ml31 vWF and 2 Wg ml31 botrocetin in the presence
of an KIIbL3 integrin blocker (10 WM Ro 43-5054) was normal in
PLCQ2 3/3 mice. The aggregation pro¢les are representative of
three separate experiments.
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Fig. 3. Morphological changes during collagen-induced activation of
PLCQ2-de¢cient platelets. Platelets from PLCQ2 +/+ or 3/3 mice
were activated with 50 Wg ml31 collagen in the aggregometer cuvette
(upper panel) and ¢xed at the times indicated by the letters A^G
for scanning electron microscopy. At time 0, PLCQ2 +/+ (A) and
PLCQ2 3/3 (D) cells displayed a similar discoid shape typical of
resting platelets. Collagen induced a rapid shape change (B) and
formation of tightly packed aggregates (C) in wild-type platelets.
PLCQ2-de¢cient cells did not change shape during the ¢rst 3 min
following collagen activation and formed comparatively small aggre-
gates (E). A late and reversible shape change was observed in these
platelets after 4^5 min (F,G). The scale bar corresponds to 2 Wm.
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mice for 3^4 min following collagen addition (Fig. 3E). After
4^5 min, concomitant with the drop in light transmission, the
platelets became more spherical and extended ¢lopodia (Fig.
3F). These morphological changes were nevertheless transient,
since at 5^6 min the cells recovered their discoid shape (Fig.
3G).
3.4. Collagen-induced granule secretion is strongly decreased in
PLCQ2-de¢cient platelets
The role of PLCQ2 in platelet secretion was evaluated using
[3H]serotonin-loaded platelets. Maximal [3H]serotonin release
was obtained in both PLCQ2 3/3 (83V 11%) and PLCQ2 +/+
(84V 2%) cells upon stimulation with 0.5 U ml31 thrombin
(Fig. 4). However, PLCQ2-de¢cient platelets displayed little
secretion (1.25 V 0.75%) in response to bovine ¢brillar type I
collagen, whereas wild-type platelets released 49V 0,65% of
their dense granule contents.
3.5. Platelet aggregation induced by selective GPVI ligands is
abolished in PLCQ2 3/3 mice
Direct stimulation of GPVI with CRP (50 Wg ml31), con-
vulxin (4.4 nM) or JAQ1 (5 Wg ml31) crosslinked by an anti-
rat second antibody (20 Wg ml31) failed to induce platelet
aggregation in PLCQ2-de¢cient mice (Fig. 5).
3.6. Analysis of the residual collagen-induced aggregation of
PLCQ2-de¢cient platelets
The failure of PLCQ2 3/3 platelets to aggregate in response
to GPVI ligands suggested the involvement of another colla-
gen receptor, possibly integrin K2L1. Incubation with a mAb
(HmK2) against mouse K2L1 completely blocked aggregation
and shape change in PLCQ2 3/3 platelets (Fig. 6A and Table
2). To evaluate the possible activation by a pathway involving
GPVI/FcRQ and independent of PLCQ2, aggregation studies
were performed in PLCQ2 3/3 platelets in the presence of
blocking concentrations of JAQ1 (Fig. 6A) and in FcRQ chain
3/3 platelets, which also lack GPVI [23] (Fig. 6B). Aggrega-
tion in response to collagen was completely abolished under
both conditions (Fig. 6 and Table 2). Treatment with a mAb
against integrin KIIbL3 or with two unrelated PI3K inhibitors
(LY294002 (25 WM) or Wortmannin (100 nM)), also strongly
and signi¢cantly inhibited aggregation of PLCQ2 3/3 platelets
(V1% as compared toV6% at 5 min, Fig. 6A and Table 2).
Finally, the involvement of released ADP and TXA2 in the
PLCQ2-independent platelet response was evaluated by block-
ing the P2Y1 and P2Y12 receptors simultaneously with the
selective ADP antagonists MRS-2179 (100 WM) and AR-
C69931MX (5 WM) [24,25] or the TXA2 pathway by treating
the cells with 10 mM aspirin. In both cases, although the
shape change typically observed at 4^5 min was blunted, the
early aggregation triggered by collagen was not signi¢cantly
a¡ected (Fig. 6A and Table 2).
4. Discussion
The main ¢nding of this study is the existence of a PLCQ2-
independent response to collagen in platelets. Although colla-
gen-induced aggregation was severely impaired in PLCQ2-de-
¢cient platelets, some residual activation still occurred. On the
other hand, selective stimulation of GPVI with convulxin,
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Fig. 4. Collagen-induced granule secretion is strongly decreased in
PLCQ2-de¢cient platelets. PLCQ2 +/+ and 3/3 platelets, washed
and loaded with [3H]serotonin, were stimulated or not with 50 Wg
ml31 type I collagen or 0.5 U ml31 thrombin in the aggregometer
cuvette. [3H]serotonin secretion was measured in the supernatant
after 3 min and results are the meanVS.E.M. values from two sepa-
rate experiments. Comparable levels of secretion were observed fol-
lowing thrombin activation whereas collagen-induced secretion was
severely decreased in PLCQ2-de¢cient platelets but not abolished.
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Fig. 5. Platelet aggregation in response to GPVI-selective agonists is
abolished in PLCQ2-de¢cient mice. Washed platelets from PLCQ2
+/+ or 3/3 mice were stimulated with 4.4 nM convulxin, 50 Wg
ml31 CRP or 5 Wg ml31 crosslinked JAQ1. These GPVI-selective
agonists induced a full aggregation response in PLCQ2 +/+ platelets
but did not activate PLCQ2 3/3 cells. These results are from one
experiment, representative of three.
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CRP or crosslinked JAQ1 mAb completely failed to induce
platelet activation in PLCQ2 3/3 mice. The low level aggre-
gation in response to collagen required mobilisation of both
GPVI and integrin K2L1 and led to integrin KIIbL3 activation
and to a late shape change triggered by TXA2 production and
ADP secretion. Agonists acting through G protein-coupled
receptors were also found to activate platelets independently
of the PLCQ2 pathway.
We con¢rmed the previous study of Wang et al. [15], and
observed 33% perinatal mortality in PLCQ2 3/3 mice often
accompanied by spontaneous gastrointestinal and intraperito-
neal bleeding. Our work further revealed the existence of a
prolonged bleeding time, pointing to a defect of primary hae-
mostasis. This defect could not be attributed to a decreased
platelet count or abnormal platelet structure (data not
shown). Moreover, PLCQ2 de¢ciency did not a¡ect the cell
surface expression of various adhesive receptors including
GPVI and integrin K2L1 (Table 1), indicating that the haemo-
static abnormality more likely resided at the signalling level.
Bleeding times in PLCQ2 3/3 mice were moderately increased
compared to those reported in integrin L3 3/3 [26] and GPIbK
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Fig. 6. Study of the receptors and signalling partners involved in
collagen-induced aggregation of PLCQ2-de¢cient platelets. A:
Washed PLCQ2 3/3 platelets were stimulated with 50 Wg ml31 col-
lagen in the aggregometer cuvette after pretreatment with inhibitors
or antibodies blocking speci¢c receptors or signalling partners: 10 Wg
ml31 HmK2 (mAb blocking K2L1), 10 Wg ml31 JAQ1 (mAb blocking
GPVI), 10 Wg ml31 RAM.2 (mAb blocking KIIbL3), 25 WM
LY294002 or 100 nM Wortmannin (PI3K inhibitors), 10 mM aspi-
rin (ASA) or 100 WM MRS-2179 and 5 WM AR-C69931MX (P2Y1
and P2Y12 antagonists respectively). Typical aggregation curves are
shown. The baseline is represented by a brocken line. B: Washed
FcRQ-de¢cient platelets were stimulated with 50 Wg ml31 collagen.
Table 2
Aggregation responses to 50 Wg ml31 bovine collagen of PLCQ2 +/+
and PLCQ2 3/3 platelets and e¡ects of speci¢c inhibitors on PLCQ2
3/3 residual aggregation
The amplitude of aggregation was expressed as the mean percentage
in light transmissionVS.E.M. at 3 min. The statistical signi¢cance
of di¡erences between PLCQ2 +/+ and PLCQ2 3/3 platelets (upper
bracket) and between untreated and treated PLCQ2 3/3 samples
was determined by a Student’s t-test. n indicates the number of sep-
arate experiments.
Table 1
Surface expression of di¡erent glycoproteins on wild-type and
PLCQ2 3/3 platelets
PLCQ2 +/+ PLCQ2 3/3
K2L1 5.4V 0.2 6.3 V 1
GPVI 6V 0.3 5.1 V 0.5
GPV 12.4V 1.5 15.5V 2.1
GPIbK 15V 6 21V 7
GPIbL 36V 5.6 44V 5.2
KIIbL3 53V 1.3 53V 4.7
CD9 92V 32 94V 15
Surface expression of the glycoproteins was measured by £ow cyto-
metry on PLCQ2 +/+ and PLCQ2 3/3 platelets. Results are ex-
pressed as mean £uorescence intensity valuesV S.D. from three
platelet preparations for each group of mice.
FEBS 27179 22-4-03
P. Mangin et al./FEBS Letters 542 (2003) 53^59 57
3/3 mice [27] but were comparable with those reported in
mice immunologically depleted of GPVI [6]. These results il-
lustrate the importance of the GPVI/PLCQ2 activation path-
way for normal haemostasis and as a potential pharmacolog-
ical target. Integrin K2L1-de¢cient mice had normal bleeding
time [7,9] in agreement with a secondary role of this receptor
for full platelet activation.
The major defect of PLCQ2 3/3 platelets was a profound
decrease in collagen-induced aggregation, which was observed
even for high concentrations of collagen. This con¢rmed the
importance of this pathway in collagen-triggered platelet acti-
vation [4]. However, contrary to an initial report [15], a re-
sidual collagen response was observed with slight progressive
aggregation but no initial shape change. This was not merely
due to trapping of platelets by the collagen ¢bres as platelet to
platelet contacts were observed by electron microscopy. Fur-
ther indication of a true aggregation response was its block-
ade by two integrin KIIbL3 antagonists, the mAb RAM.2 and
the Ro 43-5054 compound (data not shown), and in the ab-
sence of added ¢brinogen. One remarkable feature of this
aggregation was that it occurred without obvious platelet
shape change during the initiation phase.
It was reported very recently that PLCQ2-de¢cient platelets
aggregated fully in response to high concentrations of collagen
[28]. No information was available on the nature of the plate-
let aggregates and their structure. Although our study agrees
with the existence of a PLCQ2-independent response to colla-
gen, a much lower level of aggregation was observed in PLCQ2
de¢ciency even after strong collagen stimulation. This discrep-
ancy is not easily explained as both studies were performed
with the same mouse strain. One possible reason for the di¡er-
ent aggregation response could reside in the platelet prepara-
tion, since we used washed platelets and Cho et al. [28] ci-
trated platelet-rich plasma. Enhanced aggregation to weak
agonists is known to occur when [Ca2þ]i is decreased to mi-
cromolar [29]. The di¡erence was not explained by the source
of collagen as we also observed a weak aggregation with the
same commercial source of equine collagen. The aggregation
response to equine collagen at 10 Wg ml31 was comparable to
that obtained with 50 Wg ml31 bovine collagen (9% versus 7%
amplitude at 4 min) and showed similar sensitivities to antag-
onists such as the PI3K inhibitor LY294002. However this
collagen was not used in further studies as it gave in our
hands less consistent responses between experiments. In addi-
tion, with concentrations above 10 Wg ml31 this reagent sig-
ni¢cantly decreased light transmission baseline values prevent-
ing correct calibration of the aggregometer and amplitude
measurements and precluding meaningful dose^response stud-
ies. Aggregation experiments with bovine collagen responses
have therefore been presented throughout this study. Cho et
al. [28] interpreted their results as evidence for separate re-
sponses to low and high collagen concentrations with the
latter being independent of PLCQ2. From the lack of sensitiv-
ity of the response to TXA2 and ADP receptor blockade, they
suggested the existence of a secretion independent signalling
pathway speci¢c for high collagen concentrations. The present
results of a low level of aggregation in PLCQ2-de¢cient plate-
lets and the use of GPVI-speci¢c ligands and antagonists of
GPVI and integrin K2L1 are better explained by signalling
mechanism triggered by the functional association of the
two main collagen receptors.
However, this pathway only plays a synergistic role com-
pared to the strong activation mediated by the GPVI/PLCQ2-
dependent pathway. The failure of PLCQ2 3/3 platelets to
respond to GPVI agonists such as CRP, convulxin or anti-
body-crosslinked JAQ1 reveals, unlike in collagen stimulation,
an absolute need for PLCQ2 in a pathway immediately down-
stream of GPVI, in agreement with a model proposed by
several authors [1,4,30]. Since no response was observed
even at concentrations of convulxin (a stronger agonist than
collagen) inducing maximal aggregation and secretion in wild-
type platelets, its absence could not be attributed to insu⁄-
cient stimulation. This also agrees with the conventional role
of GPVI in a full collagen response, known to involve signal-
ling through PLCQ2, but does not provide an explanation for
the collagen-induced aggregation and shape change observed
in PLCQ2 3/3 platelets.
Collagen di¡ers from GPVI-speci¢c ligands in that it is
multivalent, which allows it to bind to other receptors. Earlier
studies have implicated integrin K2L1 in platelet activation
[31,32] and patients lacking this integrin present defects of
collagen-induced platelet adhesion and aggregation [33]. The
recent inactivation of K2L1 in mice played down the impor-
tance of this receptor for triggering of a full response, but did
not rule out a role of K2L1, particularly in view of the ob-
served defective aggregation and adhesion of K2L1 3/3 plate-
lets on soluble collagen [7]. The blockade of the collagen
response in PLCQ2 3/3 platelets by a mAb against integrin
K2L1 strongly supports an additional contribution of this re-
ceptor to collagen-dependent signalling.
Despite the lack of response to selective GPVI ligands, the
fact that JAQ1 blocked collagen activation in PLCQ2 de¢-
ciency nevertheless points to the involvement of GPVI. This
result, together with the absence of a collagen response in
platelets depleted of GPVI by chronic JAQ1 treatment and
in FcRQ 3/3 platelets [5,6,30,34], suggests that K2L1 needs to
be activated by GPVI for inducing a collagen signalling lead-
ing to integrin KIIbL3 mobilisation and aggregation. The re-
quirement for GPVI/FcRQ in a response distinct from the
classical GPVI//FcRQ/PLCQ2 signalling pathway was unex-
pected. It raises the question of a possible separate functional
association involving GPVI, FcRQ and K2L1, as for example in
raft microdomains requiring crosslinking by collagen ¢bres.
GPVI/FcRQ association with raft formation has been demon-
strated following stimulation with convulxin, which was ap-
parently insu⁄cient to trigger activation in PLCQ2 3/3 plate-
lets, but not following treatment with collagen [35,36]. Use of
LY294002 and Wortmannin indicated a key role of PI3K
activities in KIIbL3-dependent collagen-triggered activation in
the absence of PLCQ2. PI3K could also be implicated in
GPVI-dependent activation of K2L1, as suggested by Jung
and Moroi from studies of the binding of soluble collagen
to this integrin [37].
ADP and TXA2 were not involved in the pathway leading
to KIIbL3 activation but were required for delayed shape
change. Levels of TXA2 and ADP production were not mea-
sured but were probably very low in view of the limited ag-
gregation and minimal serotonin secretion in response to col-
lagen. This level of secretion was calculated to produce V35
nM ADP in the aggregation cuvette, a concentration su⁄cient
to induce shape change of resting washed platelet. Secretion
and shape change were abolished when the platelets were pre-
treated with RAM.2, suggesting that these responses resulted
at least in part from KIIbL3 outside-in signalling.
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Many important physiological agonists such as ADP,
thrombin, TXA2 or serotonin signal through seven transmem-
brane domain receptors coupled to GKq proteins which sub-
sequently activate PLCL [12]. Our results agree with this mod-
el in that they showed normal responses to all these agonists
in PLCQ2-de¢cient mice. There have been reports that throm-
bin could also act through PLCQ2, notably on the basis of its
phosphorylation after stimulation of platelets with thrombin
[38]. Our ¢ndings do not support this hypothesis. Although
some studies have implicated PLCQ2 in GPIb/vWF signalling
[39], we observed no abnormalities of platelet agglutination in
response to vWF, which suggests that PLCQ2 is not involved
in regulating GPIb binding. Its role in GPIb-mediated intra-
cellular signalling nevertheless remains to be determined.
In conclusion, this study has demonstrated an absolute re-
quirement for PLCQ2 in GPVI signalling and its crucial but
incomplete requirement for collagen-triggered responses. The
PLCQ2-independent collagen signalling pathway requires
GPVI in association with integrin K2L1 and leads to activation
of integrin KIIbL3, but the nature of the link between GPVI
and K2L1 and details of the pathway leading to KIIbL3 remain
to be explored. The existence of multiple receptors and signal-
ling pathways for collagen-induced platelet activation could
be a way of avoiding severe bleeding in phenotypes bearing
a genetic defect in one of these membrane proteins or intra-
cellular enzymes.
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